Hahn Offers Upbeat User-Fee Prediction At AdvaMed Conference
The US FDA commish praised the medical device community's work in response to the COVID-19 pandemic and predicted that communication developed with industry during the crisis may ease upcoming MDUFA negotiations.
You may also be interested in...
For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
The US Court of Appeals for the Ninth Circuit found that Sensory NeuroStimulation Inc., which makes a device to treat restless leg syndrome, hadn’t exhausted all administrative remedies.